NEUROMUSCULAR

Ra Pharmaceuticals’ macrocyclic peptide inhibitor of complement component 5 is expected to enter phase 3 of its development in the latter half of 2019 after success in a phase 2 trial of its potential in myasthenia gravis.
Neurology News Network for the week ending September 7, 2019.

SAP Partner Banner

About NeurologyLive's Neuromuscular Clinical Focus page:

The NeurologyLive Neuromuscular Clinical Focus page provides the latest clinical updates about neuromuscular diseases, with articles and videos covering the most up-to-date advancements in the field. Visitors to the clinical focus page will find information on emerging treatment options, as well as updates from the world’s top neurology conferences and annual meetings, including key coverage on rare disorders like ALS, DMD, and MD.

Additionally, articles and video editorial from neurologists and professionals specializing in neuromuscular conditions can be found on this page, offering expert guidance on current management strategies and potential neuromuscular therapy options.